Spica Therapeutics secured €10 million in Seed funding to advance its macrophage-targeted therapies, co-led by Bioqube Ventures and FFTF.

Target Information

Spica Therapeutics, a leading biotech company based in Antwerp, Belgium, is at the forefront of innovating therapies through the transformation of macrophage biology. Established with a research facility in Aarhus, Denmark, Spica utilizes its proprietary functional macrophage fingerprinting technology to differentiate and selectively target disease-relevant macrophage subsets. This unique approach aims to tackle significant unmet medical needs across oncology, fibroinflammatory, and autoimmune diseases.

The foundation of Spica’s initiatives is built on pioneering research from esteemed institutions, including the University of Aarhus, University of Southern Denmark, and INSERM Centre d'Immunologie de Marseille-Luminy. With a focus on advancing its lead anti-CD163 depleting monoclonal antibody assets into early Investigational New Drug (IND) enabling studies, Spica seeks to fulfill its promise of innovative therapeutics.

Industry Overview

The biotechnology sector in Belgium has been experiencing significant growth, emerging as a European hub for life sciences innovation. Fueled by a conducive ecosystem comprising research institutions, biotech firms, and strong venture capita